Mina Riad

• 8+ years of experience in the pharmaceutical industry as a clinical research.
• Expert in creating master documents and templates ( eCRFs, DMP, UAT..etc) to help new CROs to work faster and more efficient.
• Efficient professional with 6+ years of combined experience of medical and pharmaceutical
knowledge, working globally with pharmaceutical companies, Retail Pharmacy experience, Clinical Research organizations, Health Economics and Outcomes Research (HEOR), Real World
Data (RWD), Population Health, Data Analytics, literature review, medical writing, and Marketing.
• Clinical trials data management, including designing data capture tools, capturing, and recording
clinical trials data, monitoring, and promoting the quality and integrity of data, and preparing
summary reports.
• Collaborations with medical affairs teams, market access, and commercial with data analytics, and
provide medical pharmaceutical review and input as a pharmacist.
• Expert in RWE globally, during Upjohn Merged to Viatris, I completed careful documentation and
assessment of twenty major health care companies in terms of real world data assets and
capabilities.
• Post Marketing Research Experience in Medical Affairs Group
• Served as a key strategic role in project teams.
• Excellent presentation and verbal communication skills

Two chapters: “Real World Evidence in a Patient Centric Digital Era”

Our book is a Most Valuable Data & Insights Initiative Award Finalist, Reuters Events Pharma Awards USA 2022

1.Diana Morgenstern, Mina B. Riad, Claudia Zavala, and Amrit Ray. Chapter 4.Patient centricity and Precision Medicine. 

Real-World Evidence in a Patient-CentricDigital Era, Taylor & Francis, July 2022 (Completed).

Abstract: 

Patient centricity is the design and delivery of healthcare processes, whether they be research or care, with the person’s physical and mental needs in mind with an open and sustained engagement of that person so that the best experience and outcome is achieved by them, their family and the community. According to Yoeman et al. (2017), patient centricity is “defined as 'Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family'. Important principles for patients focused on education/information, cocreation, access and transparency.” Thus, such an approach results in the patient being an integral part of the process, being able to determine how the process impacts on them and can lead to better outcomes and satisfaction for the person. In this chapter, patient voice and journey-mapping are presented, along with precision medicine and personalized medicine, which are important concepts to support patient centricity. (Key Words: Patient Centricity; Patient Voice; Patient Journey; Precision Medicine; Personalized Medicine.)

_______________________________

Abstract “Treatment and comorbidities of patients with erectile dysfunction before and during COVID-19 in the United States”

Jan 2020 - Sep 2021

Abstract: 

Treatment and comorbidities of patients with erectile dysfunction before and during COVID-19 in the United States”:Irwin Goldstein, Tarek A. Hassan, Jim Z. Li, Mina B. Riad, Shivani Ohri Vignesh, Kelly H. Zou. Treatment and comorbidities of patients with erectile dysfunction before and during COVID-19 in the United States: A real-world data analysis. World Meeting on Sexual Medicine (WMSM). Virtual. November 2021. Introduction: Erectile dysfunction (ED) is usually a symptom of another medical condition. People with poor overall health are more likely to develop severe form of coronavirus disease 2019 (COVID-19) and may have unwanted symptoms such as ED. COVID-19-related stress, anxiety, and depression can also impact sexual health and possibly lead to ED. There are various treatment options for patients with ED. However, real-world evidence of the impact of COVID-19 on the treatment and comorbidities of patients with ED is limited.Objectives: To estimate the impact of COVID-19 on the treatment and comorbidities of patients with ED in the United States.Methods: This retrospective real-world data (RWD) analysis used the IQVIA PharMetrics® Plus claims database, which is a patient-Centric, closed claims database of fully adjudicated pharmacy, hospital and medical claims anonymized at the patient level, that captures the complete patient journey for all services billed to and covered by the patient’s health plan. We compared the ED treatment and comorbidities in adult males aged 18+ years with ED in the same 3-month periods before (01March - 31May, 2019) and during (01March – 31May, 2020) the COVID-19 pandemic. ED treatment included any ED-related claims, prescriptions of any and individual phosphodiesterase-5 inhibitor (PDE5i) medications (avanafil, sildenafil, tadalafil and vardenafil).